News Future uncertain for Innate and BMS' troubled lirilumab Doubts over future of cancer immunotherapy
News Innate and BMS' immunotherapy fails in phase 2 trial French biotech developing cancer immunotherapy with BMS.
News Some good news for BMS with Opdivo + natural killer cell com... But BMS dumps combination with Yervoy.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
